GMAB
Price
$20.55
Change
+$0.42 (+2.09%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
12.6B
13 days until earnings call
GNMSF
Price
$200.00
Change
+$1.90 (+0.96%)
Updated
Apr 23 closing price
Capitalization
12.6B
Ad is loading...

GMAB vs GNMSF

Header iconGMAB vs GNMSF Comparison
Open Charts GMAB vs GNMSFBanner chart's image
Genmab A/S ADS
Price$20.55
Change+$0.42 (+2.09%)
Volume$17.73K
Capitalization12.6B
Genmab A/S
Price$200.00
Change+$1.90 (+0.96%)
Volume$199
Capitalization12.6B
GMAB vs GNMSF Comparison Chart
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMAB vs. GNMSF commentary
Apr 25, 2025

To understand the difference between Genmab - ADR (GMAB) vs. Genmab (GNMSF) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (GMAB: $20.54 vs. GNMSF: $204.29)
Brand notoriety: GMAB and GNMSF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 51% vs. GNMSF: 7%
Market capitalization -- GMAB: $12.6B vs. GNMSF: $12.6B
GMAB [@Biotechnology] is valued at $12.6B. GNMSF’s [@Biotechnology] market capitalization is $12.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileGNMSF’s FA Score has 0 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • GNMSF’s FA Score: 0 green, 5 red.
According to our system of comparison, both GMAB and GNMSF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 5 TA indicator(s) are bullish while GNMSF’s TA Score has 4 bullish TA indicator(s).

  • GMAB’s TA Score: 5 bullish, 4 bearish.
  • GNMSF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than GNMSF.

Price Growth

GMAB (@Biotechnology) experienced а +2.50% price change this week, while GNMSF (@Biotechnology) price change was +1.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

GMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($12.6B) and GNMSF($12.6B) have the same market capitalization . GMAB (11.13) and GNMSF (11.07) have similar P/E ratio . GMAB (-3.546) and GNMSF (-3.559) have similar YTD gains . GMAB (9.7B) and GNMSF (9.7B) have comparable annual earnings (EBITDA) . GMAB (21.1B) and GNMSF (21.1B) have equal amount of cash in the bank . GMAB (1.03B) and GNMSF (1.03B) have identical debt. GMAB (21.5B) and GNMSF (21.5B) have equivalent revenues.
GMABGNMSFGMAB / GNMSF
Capitalization12.6B12.6B100%
EBITDA9.7B9.7B100%
Gain YTD-3.546-3.559100%
P/E Ratio11.1311.07101%
Revenue21.5B21.5B100%
Total Cash21.1B21.1B100%
Total Debt1.03B1.03B100%
FUNDAMENTALS RATINGS
GMAB vs GNMSF: Fundamental Ratings
GMAB
GNMSF
OUTLOOK RATING
1..100
112
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
99100
SMR RATING
1..100
4141
PRICE GROWTH RATING
1..100
5860
P/E GROWTH RATING
1..100
9696
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNMSF's Valuation (61) in the null industry is in the same range as GMAB (62). This means that GNMSF’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's Profit vs Risk Rating (99) in the null industry is in the same range as GNMSF (100). This means that GMAB’s stock grew similarly to GNMSF’s over the last 12 months.

GMAB's SMR Rating (41) in the null industry is in the same range as GNMSF (41). This means that GMAB’s stock grew similarly to GNMSF’s over the last 12 months.

GMAB's Price Growth Rating (58) in the null industry is in the same range as GNMSF (60). This means that GMAB’s stock grew similarly to GNMSF’s over the last 12 months.

GMAB's P/E Growth Rating (96) in the null industry is in the same range as GNMSF (96). This means that GMAB’s stock grew similarly to GNMSF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABGNMSF
RSI
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 8 days ago
66%
Declines
ODDS (%)
Bearish Trend 17 days ago
67%
Bearish Trend 3 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IGPT38.721.11
+2.95%
Invesco AI and Next Gen Software ETF
NVBT31.010.38
+1.23%
AllianzIM U.S. Large Cp Buffer10 Nov ETF
SPFF8.590.04
+0.43%
Global X SuperIncome™ Preferred ETF
CVC.X0.108686-0.001648
-1.49%
Civic cryptocurrency
RSR.X0.008499-0.000526
-5.83%
Reserve Rights cryptocurrency

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-0.69%
GNMSF - GMAB
58%
Loosely correlated
+0.96%
AXON - GMAB
47%
Loosely correlated
+3.82%
TECH - GMAB
38%
Loosely correlated
+2.20%
ARVN - GMAB
36%
Loosely correlated
+1.45%
CRSP - GMAB
35%
Loosely correlated
-1.76%
More

GNMSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNMSF has been loosely correlated with GMAB. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GNMSF jumps, then GMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
+0.96%
GMAB - GNMSF
58%
Loosely correlated
-0.69%
RIGL - GNMSF
29%
Poorly correlated
+2.37%
ARCT - GNMSF
28%
Poorly correlated
+3.78%
ATNM - GNMSF
27%
Poorly correlated
-5.80%
AGIO - GNMSF
27%
Poorly correlated
+1.32%
More